Roivant and Pulmovant have 135 patients’ worth of Phase 2 data ready to show, and the number that matters most will be public Tuesday morning: how much mosliciguat moved pulmonary vascular resistance in people with pulmonary hypertension associated with interstitial lung disease over 24 weeks of blinded treatment. PH-ILD is a condition where approved options remain limited, and the one that exists, inhaled treprostinil (Tyvaso, approved April 2021), works through prostacyclin pathways. Mosliciguat takes a different route entirely.
That mechanistic difference is the scientific bet worth watching. Rather than stimulating native soluble guanylate cyclase the way sGC stimulators do, mosliciguat directly activates the heme-free, nitric-oxide-unresponsive form of the enzyme, the form that accumulates in damaged, oxidized tissue. The rationale is that PH-ILD lungs may be precisely the environment where that form predominates, which makes the drug potentially relevant where other sGC-targeting agents cannot act. Whether the biology translates into a measurable hemodynamic signal is what the PHocus data will answer.
Marc Humbert, Professor of Respiratory Medicine at the University Paris-Saclay, presents the topline results at 12:15 CEST (6:15 a.m. ET) at the ERS International Congress 2026 in Basel. Roivant and Pulmovant host an investor call the same day. The PHocus study was a randomized, double-blind, placebo-controlled global trial, with all participants eligible to receive mosliciguat in the open-label extension after the 24-week controlled period. That extension will eventually inform longer-term safety, but Tuesday’s readout covers the controlled period and will define whether Pulmovant has a drug worth advancing to Phase 3.
The single number to watch when the data drop is the change from baseline in pulmonary vascular resistance in the mosliciguat arm versus placebo. That endpoint drove the pivotal program for Tyvaso in PH-ILD and remains the hemodynamic anchor regulators and pulmonologists use to judge whether a new agent does meaningful work in this population.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
